Settings
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E76.15 EPS (ttm)2.40 Insider Own0.70% Shs Outstand198.29M Perf Week1.29%
Market Cap36.24B Forward P/E30.91 EPS next Y5.91 Insider Trans-38.15% Shs Float196.96M Perf Month2.17%
Income484.60M PEG2.41 EPS next Q1.29 Inst Own98.00% Short Float1.49% Perf Quarter-1.70%
Sales2.08B P/S17.45 EPS this Y-0.80% Inst Trans0.22% Short Ratio2.59 Perf Half Y9.41%
Book/sh15.77 P/B11.59 EPS next Y13.67% ROA13.70% Target Price210.59 Perf Year36.76%
Cash/sh8.99 P/C20.34 EPS next 5Y31.54% ROE17.50% 52W Range126.76 - 203.30 Perf YTD-1.23%
Dividend- P/FCF76.63 EPS past 5Y44.70% ROI10.20% 52W High-10.10% Beta0.70
Dividend %- Quick Ratio4.80 Sales past 5Y43.00% Gross Margin91.50% 52W Low44.18% ATR5.84
Employees1774 Current Ratio5.10 Sales Q/Q38.60% Oper. Margin40.90% RSI (14)49.14 Volatility2.51% 3.09%
OptionableYes Debt/Eq0.02 EPS Q/Q87.20% Profit Margin23.30% Rel Volume0.71 Prev Close183.32
ShortableYes LT Debt/Eq0.01 EarningsJan 29 BMO Payout0.00% Avg Volume1.13M Price182.76
Recom1.90 SMA200.19% SMA50-2.73% SMA2007.07% Volume799,983 Change-0.31%
Jan-08-15Reiterated UBS Buy $220 → $213
Apr-25-14Reiterated Stifel Buy $219 → $220
Mar-11-14Reiterated UBS Buy $185 → $202
Mar-11-14Reiterated Stifel Buy $207 → $219
Mar-06-14Reiterated Barclays Overweight $181 → $193
Feb-10-14Reiterated Deutsche Bank Buy $125 → $205
Jan-31-14Reiterated Stifel Buy $138 → $207
Jan-31-14Reiterated Canaccord Genuity Buy $161 → $200
Jan-31-14Reiterated Barclays Overweight $141 → $181
Jan-30-14Reiterated Brean Capital Buy $142 → $200
Jan-10-14Reiterated Barclays Overweight $127 → $141
Jan-06-14Reiterated UBS Buy $130 → $150
Jan-06-14Reiterated Canaccord Genuity Buy $138 → $161
Oct-25-13Reiterated Stifel Buy $131 → $138
Oct-25-13Reiterated Barclays Overweight $121 → $127
Jul-26-13Reiterated Barclays Overweight $118 → $121
Apr-26-13Reiterated UBS Buy $120 → $123
Sep-24-12Reiterated Canaccord Genuity Buy $115 → $132
Apr-25-12Reiterated Canaccord Genuity Buy $95 → $100
Apr-25-12Reiterated Barclays Overweight $84 → $104
Jan-26-15 08:02AM  Apple, Facebook Lead This Week's IBD 50 Earnings at Investor's Business Daily
Jan-24-15 08:02AM  Apple, Facebook Lead Top IBD 50 Earnings This Week at Investor's Business Daily
Jan-23-15 05:20PM  Minerva Neurosciences Gains on Positive Data on MIN-202 - Analyst Blog Zacks
04:00PM  Sanofi's Cerdelga Cleared in the EU for Gaucher Disease - Analyst Blog Zacks
Jan-22-15 06:00PM  BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog Zacks
05:50PM  Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst Blog Zacks
05:10PM  Endo Prices $1.2B Senior Notes Offering for Auxilium Deal - Analyst Blog Zacks
04:10PM  Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog Zacks
04:00PM  Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog Zacks
03:20PM  Merrimack Reveals Additional Data from Oncology Candidate - Analyst Blog Zacks
03:10PM  Celgene to Use Zymeworks' Azymetric Platform for New Drugs - Analyst Blog Zacks
08:56AM  Kite Pharma (KITE) in Focus: Stock Tumbles 9.2% - Tale of the Tape Zacks
08:31AM  Keryx Biopharmaceuticals (KERX) in Focus: Stock Falls by 6.8% - Tale of the Tape Zacks
Jan-21-15 05:00PM  Alnylam to Raise $450 Million Through Issuance of Shares - Analyst Blog Zacks
12:50PM  Affymetrix Hits 52-Week High on Strong Top-Line Growth - Analyst Blog Zacks
10:00AM  Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2014 Results on Thursday, January 29, 2015 Business Wire
09:18AM  Applied Genetic Technologies (AGTC) in Focus: Stock Rises 6.6% - Tale of the Tape Zacks
08:44AM  AMAG Pharmaceuticals (AMAG) in Focus: Stock Rises 5.8% - Tale of the Tape Zacks
Jan-20-15 05:00PM  Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst Blog Zacks
04:15PM  Researchers to Present New Data on Asfotase Alfa in Children with Hypophosphatasia (HPP) as well as Burden of Disease Data in Adults with HPP at ENDO 2015 Annual Meeting Business Wire
Jan-19-15 04:30PM  Celgene Up as Otezla Gains EU Approval for Two Indications - Analyst Blog Zacks
09:32AM  Alkermes plc (ALKS) in Focus: Stock Moves 6.6% Higher - Tale of the Tape Zacks
08:44AM  BioDelivery Sciences International (BDSI) in Focus: Stock Up 5% - Tale of the Tape Zacks
Jan-16-15 04:16PM  Stocks End Five-Day Slide; HDFC Bank Rises at Investor's Business Daily
02:30PM  Illumina Unveils 3 NGS Systems, Modifies Business Strategy - Analyst Blog Zacks
01:50PM  OncoMed Starts Expansion Stage Study for Solid Tumor Drug - Analyst Blog Zacks
Jan-15-15 04:30PM  Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - Analyst Blog Zacks
02:40PM  Illumina Declares Impressive Q4, 2014 Preliminary Results - Analyst Blog Zacks
02:30PM  Regado Biosciences to Merge with Tobira Therapeutics - Analyst Blog Zacks
02:10PM  Qiagen Up on CE-IVD Mark for New Liquid Biopsy Test Kit - Analyst Blog Zacks
Jan-14-15 05:10PM  BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog Zacks
02:30PM  Qiagen Up on Enzymatics' Unit Buy, ArcherDX Partnership Deal - Analyst Blog Zacks
Jan-08-15 08:02AM  5 Potential Blockbuster Drugs Set To Launch In 2015 at Investor's Business Daily
Jan-07-15 05:19PM  After-hours buzz: WD-40, Brocade, Zumiez & more at CNBC +5.61%
05:19PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:15PM  Alexion Provides Update on Phase 2 Clinical Trial with Eculizumab in Antibody Mediated Rejection (AMR) in Living-Donor Kidney Transplant Recipients Business Wire
10:43AM  Keurig, J.C. Penney highlight gainers; Micron slides on earnings at MarketWatch
Jan-06-15 10:23AM  UPDATE: Barclays Capital Initiates Coverage On Alexion Pharmaceuticals On Compelling Factors Ahead Benzinga
07:40AM  UPDATE: BTIG Initiates Coverage On Alexion Pharmaceuticals Benzinga
Jan-05-15 03:22PM  Moderna Therapeutics Raises $450 Million In Biggest Biotech Private Round Ever at Forbes
10:00AM  Alexion to Present at the J.P. Morgan 33rd Annual Healthcare Conference Business Wire
Dec-30-14 06:30AM  Alexion Completes Rolling BLA Submission to U.S. FDA for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia Business Wire
Dec-27-14 08:02AM  Facebook Among IBD 50's Top 5 Earnings Kings In 2014 at Investor's Business Daily
Dec-26-14 01:38PM  Dow, S&P 500 Hold At Record Levels; GoPro Recovers at Investor's Business Daily
Dec-23-14 05:02PM  All-Time Highs For Dow, S&P 500; Nasdaq Lags at Investor's Business Daily
Dec-22-14 08:23AM  J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015 at TheStreet
Dec-15-14 08:11AM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
06:30AM  Alexion Announces $500 Million Share Repurchase Program Business Wire
Dec-10-14 04:15PM  Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis Business Wire
Dec-08-14 09:00PM  New Data Presented at ASH Annual Meeting Enhance Clinical Knowledge of aHUS and PNH and Underscore the Effectiveness of Soliris® (eculizumab) Treatment Business Wire
06:18PM  Two Gauges That Point To Fund Buying In A Stock at Investor's Business Daily
10:41AM  Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Gurufocus
Dec-05-14 06:54PM  Inside The IBD 50: Challenging Time For Growth Stocks at Investor's Business Daily
Dec-03-14 06:41PM  3 Growth Stocks In Buy Range After Recent Breakouts at Investor's Business Daily
09:51AM  Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study Zacks
08:50AM  Stock Market News for December 03, 2014 Zacks
08:02AM  Meet 5 Big Caps Whose Earnings Are Expected To Surge at Investor's Business Daily
Dec-02-14 04:20PM  Stock Market Today: Dow Hits High As Stocks Recover at Investor's Business Daily
08:33AM  The Debate Over The Cost To Develop A New Drug at Forbes
Dec-01-14 06:58PM  Some Big Cap 20 Names Holding Up In Monday's Sell-Off at Investor's Business Daily
05:30PM  Valeant's Onexton Gel Gets FDA Approval for Acne Zacks
Nov-28-14 05:20PM  Newly Profitable Medivation Riding High On Drug Sales at Investor's Business Daily
04:00PM  Alexion's Soliris Gets Final Positive NICE Recommendation Zacks
Nov-27-14 04:46AM  NICE Issues Final Positive Recommendation for National Commissioning of Soliris® (eculizumab) for All Patients with aHUS in England Business Wire
Nov-26-14 07:02PM  UK set to give green light for expensive kidney drug at Financial Times
04:10PM  Alexion's (ALXN) Soliris Gets Orphan Drug Status in Japan Zacks
Nov-25-14 06:30AM  Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica Business Wire
Nov-20-14 02:31PM  Has Alexion Pharmaceuticals Healed From Its Bad Break? at Investor's Business Daily
Nov-18-14 12:58PM  Are consumers getting gouged on health care? at MarketWatch
Nov-17-14 06:45PM  Here Are Some Big Caps Poised To Make Gains at Investor's Business Daily
Nov-15-14 10:00AM  Longer-term Outcome Data from the Largest Prospective Trial of Soliris® (eculizumab) in aHUS Underscore the Effectiveness of Ongoing Soliris Treatment Business Wire
Nov-14-14 04:51PM  Alexion, EA: Two Top Stocks Form Good Chart Patterns at Investor's Business Daily
02:36PM  Taking Stock: Iqbal Favors Oil, Transportation, Health Care at Bloomberg
Nov-10-14 07:34PM  Big Cap 20 Stuffed With Medical Names at Investor's Business Daily
05:21PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online
10:45AM  Alexion Pharma co-founder Squinto to retire AP
06:30AM  Alexion Announces Planned Retirement of Stephen Squinto, Ph.D., Company Co-Founder and Chief Global Operations Officer, in January 2015 Business Wire
Nov-06-14 04:15PM  Researchers to Present Data on Improving the Understanding of PNH and aHUS and Underscoring the Effectiveness of Soliris® (eculizumab) Treatment at ASH 2014 Annual Meeting Business Wire
Nov-04-14 06:52PM  Top Funds Buy Ulta Beauty, Alexion, Avago at Investor's Business Daily
Nov-03-14 05:58PM  Big Cap 20: Health Care, Tech Stocks Rule The Roost at Investor's Business Daily
Oct-31-14 01:04PM  ALEXION PHARMACEUTICALS INC Financials EDGAR Online Financials
Oct-29-14 11:28AM  Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen Zacks
Oct-28-14 08:03PM  Top Holdings Of Top Health Care Funds: Alexion, Gilead, Celgene at Investor's Business Daily
Oct-27-14 07:00PM  Four Biotechs Lead Health Care Stocks In Big Cap 20 at Investor's Business Daily
06:24PM  How The Moving Averages Help Guide Your Buying And Selling Investor's Business Daily
04:51PM  Alexion Launches Every Day with HPP Campaign in Support of Hypophosphatasia (HPP) Awareness Week Business Wire
Oct-24-14 06:54PM  IBD 50 Stocks Regain Buy Points at Investor's Business Daily
04:53PM  ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
12:06PM  Alexion Pharmaceuticals (ALXN) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
09:20AM  Company News for October 24, 2014 Zacks
Oct-23-14 06:10PM  Celgene, Alexion Earnings Top Views, Send Stocks Flying Investor's Business Daily +7.30%
05:12PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:16PM  Major Indexes Close Higher; Lannett Breaks Out at Investor's Business Daily
04:15PM  Researchers to Present Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at ASN 2014 Annual Meeting Business Wire
03:08PM  Alexion Pharmaceuticals: Nice Earnings, Too Expensive? at Barrons.com
01:15PM  Alexion Beats on Earnings & Revenues in Q3, Guides Up Zacks
12:14PM  Celgene, Alexion Both Beat And Raise, Stocks Rise at Investor's Business Daily
10:28AM  Stocks Jump To Early Gains; Lannett, Alexion Break Out at Investor's Business Daily
10:00AM  Alexion Pharmaceuticals Inc Earnings Call scheduled for 10:00 am ET today CCBN
07:18AM  Alexion Pharma quarterly adj profit beats, raises forecast again Reuters
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hallal DavidChief Operating OfficerDec 18Sale182.035,4941,000,073113,122Dec 19 04:49 PM
BELL LEONARDCEODec 18Sale182.0313,7352,500,182929,941Dec 19 04:49 PM
BELL LEONARDCEODec 17Option Exercise22.9016,680381,972960,356Dec 19 04:49 PM
BELL LEONARDCEODec 17Sale177.8416,6802,966,315943,676Dec 19 04:49 PM
Brennan David RDirectorDec 15Buy186.9950093,4951,268Dec 16 05:18 PM
Veneman Ann MDirectorDec 11Sale193.031,235238,3923,447Dec 15 06:50 PM
Moriarty John BEVP & General CounselDec 11Sale195.533,570698,04220,962Dec 15 06:50 PM
BELL LEONARDCEODec 09Option Exercise22.9016,665381,629960,341Dec 09 07:37 PM
BELL LEONARDCEODec 09Sale199.9416,6653,332,000943,676Dec 09 07:37 PM
BELL LEONARDCEODec 08Option Exercise21.8159,9341,307,1561,003,610Dec 09 07:37 PM
BELL LEONARDCEODec 08Sale198.8859,93411,919,423943,676Dec 09 07:37 PM
BELL LEONARDCEODec 05Option Exercise17.9856,7211,019,8441,000,397Dec 09 07:37 PM
BELL LEONARDCEODec 05Sale197.1256,72111,181,101943,676Dec 09 07:37 PM
Carmichael ClareSVP, Chief HR OfficerDec 04Option Exercise57.0210,000570,20026,272Dec 08 04:59 PM
KELLER WILLIAM RDirectorDec 04Sale196.255,000981,2507,276Dec 08 04:59 PM
Carmichael ClareSVP, Chief HR OfficerDec 04Sale196.2510,0001,962,50016,272Dec 08 04:59 PM
Sinha VikasEVP & CFODec 03Option Exercise19.1550,000957,400212,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 03Sale198.3650,0009,918,230162,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 02Option Exercise17.9825,000449,500187,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 02Sale200.1625,0005,004,000162,770Dec 04 05:20 PM
BELL LEONARDCEONov 20Sale191.965,2101,000,112943,676Nov 24 05:28 PM
Sinha VikasEVP & CFONov 06Option Exercise17.985,693102,360168,463Nov 10 05:44 PM
Sinha VikasEVP & CFONov 06Sale195.005,6931,110,135162,770Nov 10 05:44 PM
Hallal DavidChief Operating OfficerNov 03Option Exercise20.3930,000611,736148,616Nov 04 06:36 PM
Islam SaqibSVP, Chief Strat & Port. Off.Nov 03Option Exercise89.2328,1252,509,59455,425Nov 04 06:36 PM
Sinha VikasEVP & CFONov 03Option Exercise17.9630,000538,800192,770Nov 04 06:35 PM
MACKAY MARTINEVP & Global Head of R&DNov 03Option Exercise104.869,375983,06333,801Nov 04 06:36 PM
MACKAY MARTINEVP & Global Head of R&DNov 03Sale191.529,3751,795,50024,426Nov 04 06:36 PM
Sinha VikasEVP & CFONov 03Sale190.9930,0005,729,619162,770Nov 04 06:35 PM
Islam SaqibSVP, Chief Strat & Port. Off.Nov 03Sale190.5028,1255,357,83127,300Nov 04 06:36 PM
Hallal DavidChief Operating OfficerNov 03Sale190.0130,0005,700,287118,616Nov 04 06:36 PM
Sinha VikasEVP & CFOOct 31Option Exercise17.9319,307346,186182,077Nov 04 06:35 PM
Sinha VikasEVP & CFOOct 31Sale195.1819,3073,768,340162,770Nov 04 06:35 PM
Moriarty John BSVP & General CounselOct 27Option Exercise92.6510,000926,50034,532Oct 28 05:41 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 27Option Exercise62.735,550348,140112,418Oct 28 05:41 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 27Sale188.585,9101,114,532106,508Oct 28 05:41 PM
Moriarty John BSVP & General CounselOct 27Sale189.4910,0001,894,93724,532Oct 28 05:41 PM
BURNS M MICHELEDirectorOct 17Buy167.32101,673788Dec 08 04:59 PM
Moriarty John BSVP & General CounselOct 06Option Exercise95.6510,000956,50034,532Oct 08 04:55 PM
Moriarty John BSVP & General CounselOct 06Sale179.0010,0001,790,00024,532Oct 08 04:55 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 03Option Exercise42.6610,025427,667116,893Oct 07 08:13 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 03Sale172.4110,0251,728,374106,868Oct 07 08:13 PM
BELL LEONARDCEOSep 26Sale165.1260,0009,906,901948,886Sep 26 05:52 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerSep 24Sale159.507612,122106,868Sep 26 05:53 PM
BELL LEONARDCEOSep 18Sale161.4512,3882,000,0431,008,886Sep 18 05:33 PM
BELL LEONARDCEOSep 16Option Exercise17.6532,047565,6301,053,321Sep 18 05:33 PM
BELL LEONARDCEOSep 16Sale160.2632,0475,136,0051,021,274Sep 18 05:33 PM
BELL LEONARDCEOSep 10Sale165.3812,1992,017,4711,021,274Sep 12 08:59 PM
Carmichael ClareSVP, Chief HR OfficerSep 02Sale169.4630451,51616,272Sep 04 04:34 PM
BELL LEONARDCEOAug 15Option Exercise17.6535,000617,7501,062,186Aug 18 05:46 PM
BELL LEONARDCEOAug 15Sale170.0635,0005,952,1001,027,186Aug 18 05:46 PM
BELL LEONARDCEOAug 14Option Exercise17.6535,000617,7501,062,186Aug 18 05:46 PM
BELL LEONARDCEOAug 14Sale165.9235,0005,807,3661,027,186Aug 18 05:46 PM
BELL LEONARDCEOAug 13Option Exercise17.6524,542433,1661,051,728Aug 13 07:10 PM
BELL LEONARDCEOAug 13Sale162.5224,5423,988,5941,027,186Aug 13 07:10 PM
BELL LEONARDCEOAug 12Option Exercise17.6580,4581,420,0841,107,644Aug 13 07:10 PM
BELL LEONARDCEOAug 12Sale160.1680,45812,885,9101,027,186Aug 13 07:10 PM
BELL LEONARDCEOAug 04Sale157.885,145812,2931,027,186Aug 05 04:55 PM
Hallal DavidEVP, Chief Commercial OfficerAug 04Sale158.001,349213,142118,616Aug 05 04:55 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerAug 04Sale157.421,662261,632106,944Aug 05 04:55 PM
Carmichael ClareSVP, Chief HR OfficerAug 04Sale158.2318429,11416,576Aug 05 04:54 PM
Sinha VikasEVP & CFOAug 04Sale157.821,525240,676162,770Aug 05 04:54 PM
BELL LEONARDCEOJul 30Option Exercise17.6520,489361,6311,052,820Jul 30 05:08 PM
BELL LEONARDCEOJul 30Sale165.6920,4893,394,8331,032,331Jul 30 05:08 PM
BELL LEONARDCEOJul 29Option Exercise17.651,20021,1801,033,531Jul 30 05:08 PM
BELL LEONARDCEOJul 29Sale164.931,200197,9161,032,331Jul 30 05:08 PM
BELL LEONARDCEOJul 28Option Exercise17.65105,6001,863,8401,137,931Jul 30 05:08 PM
BELL LEONARDCEOJul 28Sale162.38105,60017,146,8011,032,331Jul 30 05:08 PM
BELL LEONARDCEOJun 20Option Exercise11.9290,2801,076,1381,122,611Jun 23 06:26 PM
BELL LEONARDCEOJun 20Sale163.6090,28014,770,1871,032,331Jun 23 06:26 PM
MACKAY MARTINEVP & Global Head of R&DJun 12Option Exercise104.8625,0002,621,50049,426Jun 13 05:31 PM
MACKAY MARTINEVP & Global Head of R&DJun 12Sale166.4225,0004,160,56524,426Jun 13 05:31 PM
KELLER WILLIAM RDirectorJun 05Option Exercise96.353,425329,99915,701Jun 06 04:14 PM
KELLER WILLIAM RDirectorJun 05Sale170.003,425582,25012,276Jun 06 04:14 PM
Veneman Ann MDirectorJun 04Sale170.011,236210,1324,682Jun 06 04:14 PM
BELL LEONARDCEOMay 27Option Exercise11.9270,000834,4001,102,331May 29 05:10 PM
BELL LEONARDCEOMay 27Sale166.1670,00011,631,3491,032,331May 29 05:10 PM
BELL LEONARDCEOMay 20Option Exercise10.5270,000736,1441,102,331May 22 04:49 PM
BELL LEONARDCEOMay 20Sale155.9670,00010,917,5281,032,331May 22 04:49 PM
MACKAY MARTINEVP & Global Head of R&DMay 14Sale160.853,574574,87824,426May 15 05:11 PM
PARVEN ALVIN SDirectorMay 13Option Exercise16.8312,276206,60517,116May 15 05:11 PM
PARVEN ALVIN SDirectorMay 13Sale160.7812,2761,973,7354,840May 15 05:11 PM
BELL LEONARDCEOApr 29Option Exercise10.2966,210681,3011,098,541Apr 30 05:03 PM
BELL LEONARDCEOApr 29Sale156.2666,21010,346,2561,032,331Apr 30 05:03 PM
BELL LEONARDCEOApr 28Option Exercise10.293,79038,9991,036,121Apr 30 05:03 PM
BELL LEONARDCEOApr 28Sale155.123,790587,9051,032,331Apr 30 05:03 PM
MADRI JOSEPH ADirectorMar 11Option Exercise9.5160,000570,600239,217Mar 13 05:03 PM
MADRI JOSEPH ADirectorMar 11Sale178.6160,00010,716,300179,217Mar 13 05:03 PM
Carmichael ClareSVP, Chief HR OfficerMar 03Sale174.7730553,30516,760Mar 04 05:35 PM
PARVEN ALVIN SDirectorFeb 11Sale174.062,471430,1024,840Feb 13 05:00 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 10Sale167.311,635273,552101,308Feb 10 06:47 PM
MADRI JOSEPH ADirectorFeb 07Option Exercise4.9330,000147,900209,217Feb 10 06:46 PM
Carmichael ClareSVP, Chief HR OfficerFeb 07Sale155.561,006156,49613,765Feb 10 06:48 PM
BELL LEONARDCEOFeb 07Sale155.564,620718,672986,696Feb 10 06:48 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 07Sale155.571,610250,461113,965Feb 10 06:47 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 07Sale155.571,620252,030102,943Feb 10 06:47 PM
Wright Frank JSVP, President Alxn Pharm IntlFeb 07Sale155.571,098170,81919,670Feb 10 06:48 PM
MADRI JOSEPH ADirectorFeb 07Sale159.0030,0004,770,000179,217Feb 10 06:46 PM
Sinha VikasEVP & CFOFeb 07Sale155.571,620252,029137,900Feb 10 06:46 PM
Moriarty John BSVP & General CounselFeb 07Sale155.601,036161,19822,232Feb 10 06:46 PM